Quick and comprehensive information on psychotropic drugs for children and adolescents. -
Accurate and up-to-date - Specific to children and adolescents - Charts and tables help
decision-making - Icons and full color More about this book: The Clinical Handbook of
Psychotropic Drugs for Children and Adolescents is a unique resource to help you make the right
choices about psychotropic medications for younger patients. The fifth edition of this widely
acclaimed reference has been fully updated and expanded. - Updated information on psychiatric
disorders in children and adolescents - Unique comparison charts (dosages side effects
pharmacokinetics interactions...) that allow you to see at a glance which medication is the
most suitable for each patient - Instantly recognizable icons in full color throughout
allowing you to quickly find all the information you seek: - General information on
medications availability and indications - Drug action dosing pharmacokinetics and
related areas - Warnings and precautions - Patient-related information such as lab
monitoring recommendations nursing implications and patient advice - Clearly written patient
and caregiver information sheets as printable pdf files This book is a must for all mental
health professionals working with children and adolescents who need an up-to-date easy-to use
comprehensive summary of all the most relevant information about psychotropic drugs. New in
this edition: - New chapters on Prescribing Safely and Ethically to Children and Adolescents
Pharmacogenetic Information for Common Psychotropic Drugs and Aggression Management in
Children and Adolescents - Neuroscience-based nomenclature added to Product Availability tables
- Antipsychotic-Induced Extrapyramidal Side Effect (EPSE) chapter completely revised plus new
section on monitoring scales for EPSE - Anxiolytics section on buspirone and benzodiazepine
comparison table revised - Mood Stabilizers chapter extensively revised - Natural Health
Products comprehensively revised - New Unapproved Treatments revised including preliminary
evidence for cannabidiol and folinic acid for autism spectrum disorder and ketamine for mood
disorder - New agents: deutetrabenazine ethopropazine lemborexant lumateperone orphenadrine
tetrabenazine valbenazine viloxazine - New formulations and trade names: Austedo Caplyta
Dayvigo Drizalma Sprinkle Elepsia XR Eprontia Evekeo ODT Gocovri Hetlioz LQ Ingrezza
Invega Hafyera Jornay PM Loreev XR Lybalvi Osmolex ER Oxtellar XR Parsitan Perseris
Qelbree Qudexy XR Secuado Spritam Tyrvaya Valtoco
